263159-64-4

Basic information

• Product Name: 2-BROMO-3-METHYLBENZONITRILE
• Synonyms: 2-BROMO-3-METHYLBENZONITRILE;2-BroMo-3-Methylbenzonitrile 97%;Benzonitrile, 2-bromo-3-methyl-
• CAS NO: 263159-64-4
• Molecular Formula: C₈H₆BrN
• Molecular Weight: 196.04394
• Product Categories: Aromatic Nitriles;Bromine Compounds;C8 to C9;Cyanides/Nitriles;Nitrogen Compounds
• Mol File: 263159-64-4.mol
• Article Data: 6

Chemical Properties

• Melting Point: 67-71 °C
• Boiling Point: 286.8±28.0 °C(Predicted)
• Appearance: /
• Density: 1.51±0.1 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 2-BROMO-3-METHYLBENZONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMO-3-METHYLBENZONITRILE(263159-64-4)
• EPA Substance Registry System: 2-BROMO-3-METHYLBENZONITRILE(263159-64-4)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 263159-64-4(Hazardous Substances Data)

Usage

General Description

2-Bromo-3-methylbenzonitrile is a chemical compound with the molecular formula C8H6BrN. It is a nitrile derivative of benzene with a bromine and methyl group attached to the aromatic ring. 2-BROMO-3-METHYLBENZONITRILE is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It is also used in organic synthesis as a building block for the preparation of various other organic compounds. Additionally, 2-Bromo-3-methylbenzonitrile can be utilized in the production of liquid crystals and as a reagent in chemical reactions. Due to its versatile applications, this chemical compound is of interest to researchers and manufacturers in the pharmaceutical, agrochemical, and materials science industries.

Upstream product

• 54879-20-8 2-bromo-3-methylaniline 
• 143-33-9 sodium cyanide 
• 53663-39-1 3-methyl-2-bromobenzoic acid 
• 101421-85-6 2-bromo-3-methylbenzamide 

Downstream Products

• 220324-83-4 2-[(3-cyanophenyl)methyl]imidodicarbonic acid 1,3-bis(1,1-dimethylethyl) ester 
• 1219024-56-2 2-[2-(diphenylmethylene)hydrazino]-3-methylbenzonitrile 
• 1238333-67-9 2'-fluoro-6-methylbiphenyl-2-carbonitrile 
• 1086429-87-9 2-bromo-3-(bromomethyl)benzonitrile 
• 1269411-33-7 C₁₄H₁₇BrO₃ 
• 1268335-57-4 2-bromo-3-formylbenzyl acetate 
• 1268335-59-6 2-bromo-3-(4-hydroxybutyl)benzyl acetate 
• 1268335-60-9 2-bromo-3-(4-oxobutyl)benzyl acetate 
• 1268335-61-0 4-(3-(acetoxymethyl)-2-bromophenyl)butanoic acid 
• 1268335-62-1 methyl 4-(3-(acetoxymethyl)-2-bromophenyl)butanoate 
• 1268335-63-2 methyl 4-(3-(acetoxymethyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)butanoate 
• 1268335-69-8 2-bromo-3-(3-oxobutyl)benzyl acetate 
• 1268335-70-1 3-(3-oxobutyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl acetate 
• 1268335-68-7 (E)-2-bromo-3-(3-oxobut-1-enyl)benzyl acetate 

Relevant articles and documents

SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF

The present disclosure relates to novel compounds including formula (X) and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.

MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES

The invention relates to compounds of formula (Φ) as further defined herein and to the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to the uses thereof. The compounds and salts of the present invention inhibit anaplastic lymphoma kinase (ALK) and/or EML4-ALK and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer.

BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS

This invention provides novel compounds of the following formula useful for treating protozoal infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent.